JPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $190.00) while maintaining a Overweight ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Abbvie (ABBV) PT Raised to $200 at Goldman SachsJuly 26, 2024 5:53 AM William Blair Reiterates Outperform Rating on Abbvie (ABBV)July 26, 2024 5:37 AM Abbvie (ABBV) PT Raised to $210 at Truist SecuritiesJuly 25, 2024 4:12 PM Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends ExpectedJuly 25, 2024 8:30 AM AbbVie hikes full-year earnings guidance as Humira sales top estimatesJuly 25, 2024 7:56 AM AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidanceJuly 25, 2024 7:50 AM Form 8-K AbbVie Inc. For: Jul 25July 25, 2024 7:42 AM AbbVie lifts 2024 profit forecast, shares hit record highJuly 25, 2024 7:39 AM AbbVie Reports Second-Quarter 2024 Financial ResultsJuly 25, 2024 7:36 AM Stocks expected to have increasing option volume: ABBV TRU HAS KDP LUV WH IBM CMG NOW LVS July 25, 2024 5:17 AM AbbVie (ABBV) call put ratio 1 call to 1 put into quarter resultsJuly 24, 2024 11:21 AM AbbVie (ABBV) July weekly 172.50 straddle priced into quarter results July 24, 2024 4:42 AM